The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Curing metastatic testicular cancer
Open accessAbstract
Our initial studies with cisplatin + vinblastine + bleomycin began 27 years ago in 1974, changing the cure rate for disseminated disease from 5 to 60%. Subsequently, through random prospective clinical trials, we have modified the treatment regimen to reduce both the duration and dosages of the chemotherapy drugs. Cisplatin + etoposide was first used at Indiana University as salvage chemotherapy in 1978, representing the first time that a solid tumor had been cured with second-line chemotherapy. We next did a clinical trial comparing bleomycin + etoposide + cisplatin (BEP) to cisplatin + vinblastine + bleomycin. The BEP regimen was proven to have less toxicity and a higher cure rate and therefore, since 1984, has been standard chemotherapy. More recent studies have evaluated the use of lesser chemotherapy to maintain the same cure rate for patients with good-prognosis disease. Standard therapy for these patients is either three courses of BEP or four courses of EP, and over 90% of these patients will be cured of their disease. Patients who are not cured with their initial BEP chemotherapy are usually treated with salvage chemotherapy. Approximately 50% of these testicular cancer patients will subsequently be cured with salvage chemotherapy with tandem transplant of high-dose chemotherapy with peripheral stem cell rescue. Testicular cancer has become a model for a curable neoplasm. In the early 1970s, metastatic testicular cancer was associated with only 5% survival. Today, with modern chemotherapy and surgery techniques, 80% of patients will survive their disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode
ROSENBERG, B., VAN CAMP, L., & KRIGAS, T. (1965) · Nature · doi:10.1038/205698a0 · Cited by 3,049
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.594 · Cited by 1,929
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Self-citationWilliams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
Self-citationMead, G. M., Stenning, S. P., Cook, P. A., Fosså, S. D., Horwich, A., Kaye, S. B., Oliver, R. T. D., deMulder, P., deWit, R., Stoter, G., et al. (1997) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1,033
Effects of Combined Drug Therapy on Metastatic Cancer of the Testis
Li, M. C. (1960) · JAMA · doi:10.1001/jama.1960.03030100059013 · Cited by 409
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
Loehrer, P. J., Gonin, R., Nichols, C. R., Weathers, T., & Einhorn, L. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2500 · Cited by 397
Self-citationEinhorn, L. H., Williams, S. D., Loehrer, P. J., Birch, R., Drasga, R., Omura, G., & Greco, F. A. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.3.387 · Cited by 367
Self-citationLate relapse of testicular cancer.
Baniel, J., Foster, R. S., Gonin, R., Messemer, J. E., Donohue, J. P., & Einhorn, L. H. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1170 · Cited by 331
Self-citationSjamsoedin, L. J. M., Heijnen, L., Mauser-Bunschoten, E. P., van Geijlswijk, J. L., van Houwelingen, H., van Asten, P., & Sixma, J. J. (1981) · New England Journal of Medicine · doi:10.1056/nejm198109243051301 · Cited by 304
Cited by
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Microbial drug discovery: 80 years of progress
Demain, A. L., & Sanchez, S. (2009) · The Journal of Antibiotics · doi:10.1038/ja.2008.16 · Cited by 1,002
Karim-Kos, H. E., de Vries, E., Soerjomataram, I., Lemmens, V., Siesling, S., & Coebergh, J. W. W. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.12.015 · Cited by 754
Bleomycins: towards better therapeutics
Chen, J., & Stubbe, J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1547 · Cited by 664
Griggs, J. J., Mangu, P. B., Anderson, H., Balaban, E. P., Dignam, J. J., Hryniuk, W. M., Morrison, V. A., Pini, T. M., Runowicz, C. D., Rosner, G. L., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.9436 · Cited by 485
Metadata
- Authors
- Einhorn, L. H.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2002-03-19
- Volume
- 99
- Issue
- 7
- Pages
- 4592-4595
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2007208661
- Cited by
- 387
- References
- 12
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Curing metastatic testicular cancer. https://app.cochat.ai/papers/10.1073/pnas.072067999
- The paper
- Einhorn, L. H. (2002). Curing metastatic testicular cancer. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.072067999
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.